Results 161 to 170 of about 120,942 (241)

Dopamine Agonist-Induced Cerebrospinal Fluid Rhinorrhoea: A Case Report. [PDF]

J Cancer Allied Spec, 2021
Irfan H, Siddiqi AI, Azmat U, Shafiq W, Yousaf I, Naveed MA.   +5 more
europepmc   +1 more source

Erratum to “estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats” [Neurosci. Lett. 193 (1995) 65–67]

, 1995
Raul R. Gainetdinov, Tatyana D. Sotnikova, Tatyana V. Grekhova, K.S. Rayevsky   +3 more
openalex   +1 more source

Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI [PDF]

, 2001
Daniel Y. Kimberg, Gustavo D. Aguirre, Jessica Lease, Mark D’Esposito   +3 more
openalex   +1 more source

Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients. [PDF]

Acta Neurochir (Wien)
Ryba A, Gonzalez Lopez D, Rotermund R, Flitsch J.   +3 more
europepmc   +1 more source

Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life [PDF]

, 2001
Fabrizio Stocchi, Laura Vacca, Alfredo Berardelli, Francesca De Pandis, Stefano Ruggieri   +4 more
openalex   +1 more source

Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. [PDF]

Eur J Neurol
Staubo SC, Fuskevåg OM, Toft M, Lie IH, Alvik KMJ, Jostad P, Tingvoll SH, Lilleng H, Rosqvist K, Størset E, Odin P, Dietrichs E, Dietrichs ES.   +12 more
europepmc   +1 more source

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. [PDF]

Mov Disord, 2021
Picillo M, Phokaewvarangkul O, Poon YY, McIntyre CC, Beylergil SB, Munhoz RP, Kalia SK, Hodaie M, Lozano AM, Fasano A.   +9 more
europepmc   +1 more source

Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice [PDF]

, 2002
Rebecca J. Ralph-Williams, Virginia Lehmann-Masten, Veronica Otero-Corchón, Malcolm J. Low, Mark A. Geyer   +4 more
openalex   +1 more source

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. [PDF]

CNS Neurol Disord Drug Targets
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.   +5 more
europepmc   +1 more source

Dopamine Agonist Therapy in Advanced Parkinson’s Disease [PDF]

Journal of Movement Disorders, 2009
Heinz Reichmann
doaj   +1 more source